ProfileGDS5678 / 1452740_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 93% 92% 92% 92% 91% 84% 84% 89% 86% 95% 95% 94% 95% 94% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.8139593
GSM967853U87-EV human glioblastoma xenograft - Control 27.5949292
GSM967854U87-EV human glioblastoma xenograft - Control 37.627492
GSM967855U87-EV human glioblastoma xenograft - Control 47.9223992
GSM967856U87-EV human glioblastoma xenograft - Control 57.5512191
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.9942384
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.1274684
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.9383289
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.4971386
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.5952495
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.54595
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.2034194
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.4594795
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 58.2583894